Protagenic Therapeutics, Inc.New PTIXW
We take great care to ensure that the data presented and summarized in this overview for Protagenic Therapeutics, Inc.new is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in PTIXW
Top Purchases
Top Sells
About PTIXW
Insider Transactions at PTIXW
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 12
2023
|
Alexander K. Arrow Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
8,000
+14.87%
|
$0
$0.81 P/Share
|
|
May 18
2022
|
Alexander K. Arrow Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
8,000
+5.02%
|
$0
$0.72 P/Share
|
|
May 17
2022
|
Alexander K. Arrow Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
23,000
+13.83%
|
$0
$0.71 P/Share
|
|
May 03
2021
|
Khalil Barrage Director |
BUY
Exercise of conversion of derivative security
|
Direct |
360,000
+26.55%
|
$360,000
$1.5 P/Share
|
|
Apr 30
2021
|
Alexander K. Arrow Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+0.82%
|
$2,000
$2.29 P/Share
|
|
Apr 29
2021
|
Alexander K. Arrow Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+0.83%
|
$2,000
$2.29 P/Share
|
Last 12 Months Summary
Buy / Acquisition
8K
Shares
From
1
Insiders
| Open market or private purchase | 8K shares |
|---|
Sell / Disposition
0
Shares
From
0
Insiders